Carol Stonham MBE, a Medical Advisory Board member, has conducted this study. Carol became a registered nurse in 1986 and transitioned to primary care from acute hospital settings by 1990. Currently, she works at the Gloucestershire ICB and heads the Respiratory Clinical Programme Group, while also co-leading the NHSE South West Respiratory Network.
Image Credit: Bedfont® Scientific Ltd
This case study aims to showcase the value of Fractional exhaled Nitric Oxide (FeNO) testing in asthma care and explore why the NObreath® FeNO device is the ideal choice. The NObreath® performs a non-invasive test that measures nitric oxide levels in exhaled breath. Elevated nitric oxide levels may suggest airway inflammation, a typical characteristic of allergic asthma.
Asthma is a common respiratory condition impacting approximately 5.4 million people in the UK. Tragically, a substantial number of asthma-related deaths occur annually, with a high percentage of these deaths considered preventable. This highlights the value of increasing awareness about FeNO testing and its crucial role in asthma diagnosis and management.
Carol states:
When looking into the different devices, the NObreath® suited what I was looking for. I wanted something that had a really good approval process as I wanted something that would be reliable. I wanted something that was going to be easy for the patients to use but also easy to teach the healthcare professionals to use. The cost always comes into it, this is something we always need to be careful about within the NHS. Finally, it needed to be something that would offer a sustainable service for a long time.
Image Credit: Bedfont® Scientific Ltd
Carol continues, “The thing I like about this device is the ease of use, I like that it is portable, so if you have this in a practice setting you can move it around from A to B simply. In my experience, I’ve had patients as young as 5 and as old as 95 able to do the test. It is an all-age easy-to-use device, it doesn’t take long either, you can do it really quickly in a consultation.”
Image Credit: Bedfont® Scientific Ltd
Watch the case study
This study underscores FeNO testing’s impact on asthma care and demonstrates the advantages of utilizing the NObreath® FeNO device.
Revolutionising Asthma Care: FeNO Breath Test Insights with Carol Stonham
Video Credit: Bedfont® Scientific Ltd
With insights from Carol Stonham, the study emphasizes the NObreath’s user-friendliness, making it appropriate for adults and children. It also showcases how FeNO testing improves asthma management by providing more accurate insights for personalized care. Ultimately, this case study shows why the NObreath® FeNO device is the ideal tool for aiding in the diagnosis and management of asthma.
References and further reading
- Asthma + Lung UK (2021). What Is Asthma? (online). Available at: https://www.asthmaandlung.org.uk/conditions/asthma/what-asthma.
About Bedfont® Scientific Ltd
Bedfont® Scientific has specialised in the design and manufacture of exhaled breath and gas monitoring instruments since 1976.
For medical gas monitoring, their Medi-Gas Check medical pipeline testing range verifies not only the quantity but also quality of gas administered to patients.
Bedfont's breath analysers include carbon monoxide (CO) monitors such as the Smokerlyzer®, used for smoking cessation, and the ToxCO®, used by emergency services, to diagnose CO poisoning.
The NObreath® FeNO monitor provides accurate analysis of airway inflammation for the control of asthma, and the Gastrolyzer® range aids in the detection of gastrointestinal disorders and food intolerances. Quick and non-invasive, breath analysis is the new blood test.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.